Cellastra

Executive Summary

Cellastra Inc. is a private biotechnology company founded in 2021 and headquartered in San Francisco. The company is developing Ensereptide, a natural derivative of Lactoferrin, combined with AAV (adeno-associated virus) technology to treat fibrotic and wound healing conditions. Its primary focus areas include pulmonary fibrosis, burn injuries, and aesthetic or post-surgical applications. By leveraging the anti-inflammatory and regenerative properties of Ensereptide along with AAV-mediated gene delivery, Cellastra aims to address significant unmet medical needs in fibrotic diseases and tissue repair. The company is in an early preclinical stage, with no disclosed funding rounds or pipeline details publicly available. Given the lack of clinical data and limited corporate information, Cellastra remains a high-risk, early-stage venture. Its success will depend on generating robust preclinical proof-of-concept data, securing financing, and navigating regulatory pathways. The company operates in competitive therapeutic areas, particularly pulmonary fibrosis, where established players and novel therapies exist. However, its unique approach combining a natural peptide with gene therapy may offer differentiated benefits.

Upcoming Catalysts (preview)

• Q3 2026IND-enabling studies initiation for Ensereptide-AAV in pulmonary fibrosis15% success
• Q4 2026Preclinical efficacy data in burn injury model25% success
• Q2 2027Partnership or licensing agreement with a larger biopharma for AAV-Ensereptide platform10% success